CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Net product sales	$ 784,182	$ 544,573
Sanofi collaboration revenue	219,694	173,356
Bayer Collaboration Revenue	179,592	123,846
Other revenue	17,381	27,837
Total revenues	1,200,849	869,612
Expenses:
Research and development	470,112	343,113
Selling, general, and administrative	289,677	158,991
Cost of goods sold	78,942	42,570
Cost of collaboration and contract manufacturing	32,810	41,385
Total expenses	871,541	586,059
Income from operations	329,308	283,553
Other income (expense):
Investment income	2,249	180
Interest and other expense, net	1,406	7,210
Nonoperating Income (Expense)	843	(7,030)
Income before income taxes	330,151	276,523
Income tax expense	(164,415)	(200,502)
Net income	$ 165,736	$ 76,021
Net income per share - basic	$ 1.59	$ 0.74
Net income per share - diluted	$ 1.45	$ 0.66
Weighted average shares outstanding - basic	104,290	102,227
Weighted average shares outstanding - diluted	114,228	114,519
Statements of Comprehensive Income
Net income	$ 165,736	$ 76,021
Other comprehensive income (loss):
Unrealized loss on marketable securities, net of tax	(4,208)	(4,347)
Comprehensive income	$ 161,528	$ 71,674